170 related articles for article (PubMed ID: 23517785)
1. A new system for targeted delivery of doxorubicin into tumor cells.
Yabbarov NG; Posypanova GA; Vorontsov EA; Obydenny SI; Severin ES
J Control Release; 2013 Jun; 168(2):135-41. PubMed ID: 23517785
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of doxorubicin: drug delivery system based on PAMAM dendrimers.
Yabbarov NG; Posypanova GA; Vorontsov EA; Popova ON; Severin ES
Biochemistry (Mosc); 2013 Aug; 78(8):884-94. PubMed ID: 24228876
[TBL] [Abstract][Full Text] [Related]
3. Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes.
Wen S; Liu H; Cai H; Shen M; Shi X
Adv Healthc Mater; 2013 Sep; 2(9):1267-76. PubMed ID: 23447549
[TBL] [Abstract][Full Text] [Related]
4. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Owen DJ; Boyd BJ; Porter CJ
J Control Release; 2011 Jun; 152(2):241-8. PubMed ID: 21315119
[TBL] [Abstract][Full Text] [Related]
5. Construction and evaluation of PAMAM-DOX conjugates with superior tumor recognition and intracellular acid-triggered drug release properties.
Cheng L; Hu Q; Cheng L; Hu W; Xu M; Zhu Y; Zhang L; Chen D
Colloids Surf B Biointerfaces; 2015 Dec; 136():37-45. PubMed ID: 26360738
[TBL] [Abstract][Full Text] [Related]
6. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
7. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
[TBL] [Abstract][Full Text] [Related]
8. The receptor binding fragment of alpha-fetoprotein is a promising new vector for the selective delivery of antineoplastic agents.
Posypanova GA; Makarov VA; Savvateeva MV; Bereznikova AV; Severin ES
J Drug Target; 2013 May; 21(5):458-65. PubMed ID: 23600748
[TBL] [Abstract][Full Text] [Related]
9. Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate.
Mollaev M; Gorokhovets N; Nikolskaya E; Faustova M; Zabolotsky A; Zhunina O; Sokol M; Zamulaeva I; Severin E; Yabbarov N
Int J Pharm; 2019 Mar; 559():138-146. PubMed ID: 30599230
[TBL] [Abstract][Full Text] [Related]
10. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
Han L; Huang R; Li J; Liu S; Huang S; Jiang C
Biomaterials; 2011 Feb; 32(4):1242-52. PubMed ID: 20971503
[TBL] [Abstract][Full Text] [Related]
11. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers.
Zhong Q; Humia BV; Punjabi AR; Padilha FF; da Rocha SRP
Eur J Pharm Sci; 2017 Nov; 109():86-95. PubMed ID: 28774811
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
13. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers.
Dong DW; Tong SW; Qi XR
J Biomed Mater Res A; 2013 May; 101(5):1336-44. PubMed ID: 23065848
[TBL] [Abstract][Full Text] [Related]
15. Cellular delivery of doxorubicin mediated by disulfide reduction of a peptide-dendrimer bioconjugate.
Burns KE; Delehanty JB
Int J Pharm; 2018 Jul; 545(1-2):64-73. PubMed ID: 29709616
[TBL] [Abstract][Full Text] [Related]
16. [The Combined Effects of Ionizing Radiation and Dendritic Polymers Loaded with Doxorubicin on the MCF-7 Breast Cancer Cell Line].
Zamulaeva IA; Pronyushkina KA; Matchuk ON; Yabbarov NG; Nikolskaya ED; Kondrasheva IG
Radiats Biol Radioecol; 2015; 55(6):591-7. PubMed ID: 26964344
[TBL] [Abstract][Full Text] [Related]
17. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
[TBL] [Abstract][Full Text] [Related]
18. Poly(ethylene glycol)-modified PAMAM-Fe3O4-doxorubicin triads with the potential for improved therapeutic efficacy: generation-dependent increased drug loading and retention at neutral pH and increased release at acidic pH.
Nigam S; Chandra S; Newgreen DF; Bahadur D; Chen Q
Langmuir; 2014 Feb; 30(4):1004-11. PubMed ID: 24446987
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer.
Fu F; Wu Y; Zhu J; Wen S; Shen M; Shi X
ACS Appl Mater Interfaces; 2014 Sep; 6(18):16416-25. PubMed ID: 25185074
[TBL] [Abstract][Full Text] [Related]
20. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
